Fosfomycin
- Generic Name
- Fosfomycin
- Brand Names
- Monurol
- Drug Type
- Small Molecule
- Chemical Formula
- C3H7O4P
- CAS Number
- 23155-02-4
- Unique Ingredient Identifier
- 2N81MY12TE
- Background
Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.
Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.
- Indication
Fosfomycin is indicated for the treatment of uncomplicated cases of cystitis caused by susceptible strains of Escherichia coli and Enterococcus faecalis. Fosfomycin is not officially indicated for the treatment of pyelonephritis or perinephric abscess, although there have been reported cases of off-label usage in these situations.
- Associated Conditions
- Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infections caused by E. coli, Uncomplicated Urinary Tract Infections caused by Enterococcus faecalis
- Associated Therapies
- -
COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
- Conditions
- Urinary Tract Infections
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Shalamar Institute of Health Sciences
- Target Recruit Count
- 392
- Registration Number
- NCT06518291
Therapeutic Options for CRAB
- Conditions
- Infections, BacterialSepsis Bacterial
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Clinical Hospital Centre Zagreb
- Target Recruit Count
- 108
- Registration Number
- NCT06440304
Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections
- Conditions
- Urinary Tract Infections
- Interventions
- Drug: Standard of care antibioticsDrug: Fosfomycin
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 300
- Registration Number
- NCT05709028
- Locations
- 🇦🇺
Sydney Childrens Hospital, Sydney, New South Wales, Australia
🇦🇺The Children's Hospital at Westmead, Sydney, New South Wales, Australia
🇦🇺Royal Childrens Hospital, Melbourne, Victoria, Australia
Effect of Cranberry Extract on the Urinary System
- Conditions
- Antibiotic ReactionCystitisUrinary Tract Disease
- Interventions
- Dietary Supplement: CranberryDrug: Fosfomycin
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Kırklareli University
- Target Recruit Count
- 2
- Registration Number
- NCT05260554
- Locations
- 🇹🇷
Oya Guven, MD, Kirklareli, Center, Turkey
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
- Conditions
- Urinary Tract Infections
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- MJM Bonten
- Target Recruit Count
- 13
- Registration Number
- NCT05254808
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇳🇱Medisch Centrum Heuvelrug, Doorn, Utrecht, Netherlands
🇳🇱Huisartsenpraktijk Binnenstad, Utrecht, Netherlands
Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 226
- Registration Number
- NCT05211011
- Locations
- 🇩🇪
Universitätsmedizin Mainz, Mainz, Germany
🇩🇪Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Städtisches Klinikum Dresden, Dresden, Germany
Bearberry in the Treatment of Cystitis
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- University of Pecs
- Target Recruit Count
- 504
- Registration Number
- NCT05055544
- Locations
- 🇭🇺
Institute for Translational Medicine, University of Pécs, Pécs, Hungary
The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
- Conditions
- Antibiotic Resistant Infection
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03950544
- Locations
- 🇨🇳
Shanghai 10th people's hospital, Shanghai, Shanghai, China
Intravenous Fosfomycin Pharmacokinetics Study
- Conditions
- Multiple-drug ResistancePathogen ResistanceBacterial Infection
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 39
- Registration Number
- NCT03910673
- Locations
- 🇺🇸
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)
- Conditions
- Urinary Tract Infection
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2020-12-19
- Target Recruit Count
- 62
- Registration Number
- NCT03697993
- Locations
- 🇺🇸
Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.